<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cytomegalovirus immune globulin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cytomegalovirus immune globulin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cytomegalovirus immune globulin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9315" href="/d/html/9315.html" rel="external">see "Cytomegalovirus immune globulin: Drug information"</a> and <a class="drug drug_patient" data-topicid="11714" href="/d/html/11714.html" rel="external">see "Cytomegalovirus immune globulin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F156155"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cytogam</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52911966"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cytogam</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1046791"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Immune Globulin</span></li></ul></div>
<div class="block dop drugH1Div" id="F15670247"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cb9b54ae-308e-4154-abc8-49d7a1d907e1">Solid organ transplantation; prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid organ transplantation; prophylaxis: </b>
<b>Note:</b> Antiviral medications are recommended for CMV prophylaxis; there is limited data to support the addition of cytomegalovirus immunoglobulin (CMV-Ig) to antiviral medication for prophylaxis. Some centers use both antiviral medications and CMV-Ig for high-risk transplants, such as thoracic or intestinal transplant based on donor and recipient CMV status (Nagai 2016; Transplantation Society International [Kotton 2013])</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Heart or lung </i>
<i>transplant: </i>Infants, Children, and Adolescents: IV: 150 mg/kg within 72 hours of transplant; 150 mg/kg at weeks 2, 4, 6, and 8 after transplant; 100 mg/kg at weeks 12 and 16 after transplant; specific number of doses and duration may vary among patients and institutional protocols</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Kidney transplant:</i> Infants, Children, and Adolescents: Initial: IV: 150 mg/kg within 72 hours of transplant; 100 mg/kg at weeks 2, 4, 6, and 8 after transplant; 50 mg/kg at weeks 12 and 16 after transplant; specific number of doses and duration may vary among patients and institutional protocols</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Liver, pancreas, or intestine</i>: Limited data available in small bowel transplantation (Nagai 2016; Transplantation Society International [Kotton 2013]); dosing regimens variable; CMV risk stratification (ie, donor [D] and recipient [R]; CMV status either positive [+] or negative [-]) is suggested (Transplantation Society International [Kotton 2013]):</p>
<p style="text-indent:-2em;margin-left:6em;">Low and moderate risk (D-/R-, D-/R+, D+/R+): Limited data available: Infants, Children, and Adolescents: IV: 150 mg/kg once 7 days after transplant (Nagai 2016)</p>
<p style="text-indent:-2em;margin-left:6em;">High risk (D+/R-): Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Fixed bi-weekly dosing: IV: 150 mg/kg within 72 hours of transplant; 150 mg/kg at weeks 2, 4, 6, and 8 after transplant; then 100 mg/kg at weeks 12 and 16 after transplant</p>
<p style="text-indent:-2em;margin-left:8em;">Reduced frequency dosing: IV: 150 mg/kg twice weekly for 2 weeks, then weekly for 2 weeks, then every other week for 4 weeks, then monthly for 2 months; if serum CMV IgG negative at that time, continue monthly to 1 year total therapy following transplantation; if CMV IgG positive, discontinue therapy (Nagai 2016)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b852cd3a-3351-4f14-9c32-597081eef760">Treatment, CMV disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Treatment, CMV disease:</b> Limited data available (Martin 2011):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ganciclovir-resistant infection and disease:</i> Infants, Children, and Adolescents: IV: 100 mg/kg/dose weekly in combination with other antivirals (eg, ganciclovir, foscarnet, cidofovir); duration of therapy dependent upon CMV antigenemia assay (pp65) or PCR (Bueno 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pneumonitis, severe; in combination with ganciclovir</i>: Dosing regimens variable: Children and Adolescents: IV: 400 mg/kg on days 1, 2, and 7 followed by 200 mg/kg on days 14; if still symptomatic, may administer an additional 200 mg/kg on day 21 (Reed 1988); others have used in patients ≥18 years of age a dose of 150 mg/kg twice weekly (Alexander 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Post-solid organ (visceral) transplantation, development of viremia during prophylaxis (detectable CMV polymerase chain reaction [PCR] &gt;250 copies/mL): </i>Infants, Children, and Adolescents: IV: 150 mg/kg every 48 hours for at least 3 doses, then continue to taper by reducing dosing frequency similar to prophylaxis schedule (eg, doses administered twice weekly, followed by weekly, every other week, then monthly; monitor CMV PCR weekly until criteria met [eg, two results are undetectable]); used in combination with antiviral medications (eg, ganciclovir, valganciclovir, foscarnet, cidofovir) (Nagai 2016)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="700b9351-f381-4f53-a845-ed4c7496edfd">Infantile autoimmune hemolytic anemia, CMV-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infantile autoimmune hemolytic anemia, CMV-associated: </b>Very limited data available: Infants: IV: 500 mg/kg CMV Ig followed by 3 days of standard IV immune globulin (IVIG); dosing based on case reports in a 4 month old and an 11 month old who failed to respond to corticosteroids and PRBC transfusions (Murray 2001)</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51090500"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling; use with caution. Infuse at minimum rate possible.</p></div>
<div class="block dohp drugH1Div" id="F51108755"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F156157"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9315" href="/d/html/9315.html" rel="external">see "Cytomegalovirus immune globulin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c6be27d9-e7b0-4e8f-83bc-20e26ad030c1">Prophylaxis of CMV disease in kidney transplant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prophylaxis of CMV disease in kidney transplant:</b> IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Initial dose (within 72 hours of transplant): 150 mg/kg/dose</p>
<p style="text-indent:-2em;margin-left:4em;">2-, 4-, 6-, and 8 weeks after transplant: 100 mg/kg/dose</p>
<p style="text-indent:-2em;margin-left:4em;">12- and 16 weeks after transplant: 50 mg/kg/dose</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c787bd25-0ea7-424e-b407-50bcecb581a7">Prophylaxis of CMV disease in liver, lung, pancreas, or heart transplant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prophylaxis of CMV disease in liver, lung, pancreas, or heart transplant:</b> IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Initial dose (within 72 hours of transplant): 150 mg/kg/dose</p>
<p style="text-indent:-2em;margin-left:4em;">2-, 4-, 6-, and 8 weeks after transplant: 150 mg/kg/dose</p>
<p style="text-indent:-2em;margin-left:4em;">12- and 16 weeks after transplant: 100 mg/kg/dose</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="28cacbbd-5dfa-4297-a988-c1b06a9cf61e">Treatment of severe CMV pneumonitis in hematopoietic stem cell transplant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Treatment of severe CMV pneumonitis in hematopoietic stem cell transplant (off-label use; in combination with ganciclovir):</b> IV: 400 mg/kg on days 1, 2, and 7, followed by 200 mg/kg on day 14; if still symptomatic, may administer an additional 200 mg/kg on day 21 (Reed, 1988) <b>or</b> 150 mg/kg twice weekly (Alexander, 2010)</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990160"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Infuse at minimum rate possible.</p></div>
<div class="block doha drugH1Div" id="F50987495"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F156134"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;6%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Chills</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, back pain, muscle cramps</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Wheezing</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing and/or case reports: Abdominal pain, acute renal failure, acute respiratory distress, anaphylactic shock, angioedema, anuria, apnea, aseptic meningitis, bronchospasm, bullous dermatitis, circulatory shock, coma, cyanosis, decreased blood pressure, dyspnea, epidermolysis, erythema multiforme, hemolysis, hepatic insufficiency, hypersensitivity reaction (systemic), hypotension, hypoxemia, increased blood urea nitrogen, increased serum creatinine, leukopenia, loss of consciousness, oliguria, osmotic nephrosis, pancytopenia, positive direct Coombs test, proximal tubular nephropathy, pulmonary edema, renal insufficiency, renal tubular necrosis, rigors, seizure, Stevens-Johnson syndrome, thromboembolism, transfusion-related acute lung injury, tremor</p></div>
<div class="block coi drugH1Div" id="F156147"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of severe hypersensitivity to cytomegalovirus immune globulin IV (human), other human Ig preparations, or any component of the formulation; selective Ig A deficiency</p></div>
<div class="block war drugH1Div" id="F156132"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; discontinue immediately for hypotension or anaphylaxis; immediate treatment (including epinephrine 1 mg/mL) should be available. Systemic allergic reactions are rare; may be treated with epinephrine and diphenhydramine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Aseptic meningitis: Aseptic meningitis syndrome (AMS) has been reported with intravenous immune globulin administration (rare); may occur with high doses (≥2 g/kg). Symptoms include severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements and nausea and vomiting. Syndrome usually appears within several hours to 2 days following treatment; usually resolves within several days after discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolysis: Intravenous immune globulin has been associated with antiglobulin hemolysis; monitor for signs of hemolytic anemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary edema: Monitor for adverse pulmonary events including transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with intravenous immune globulin use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, and fever in the presence of normal left ventricular function and usually occurs within 1 to 6 hours after infusion; may be managed with oxygen and respiratory support.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Acute renal dysfunction (increased serum creatinine, oliguria, osmotic nephrosis, acute renal failure) can rarely occur; more likely with products stabilized with sucrose. Patients at risk for renal failure include the elderly, patients with preexisting renal disease, diabetes mellitus, volume depletion, sepsis, paraproteinemia, and nephrotoxic medications. In patients at risk of renal dysfunction, the rate of infusion and concentration of solution should be minimized. Discontinue if renal function deteriorates.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic events: Thrombotic events have been reported with administration of intravenous immune globulin; patients at risk include those with advanced age or a history of atherosclerosis, cardiovascular and/or thrombotic risk factors, or known/suspected hyperviscosity. Consider a baseline assessment of blood viscosity in patients at risk for hyperviscosity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypovolemia: Patients should not be volume depleted prior to therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in patients &gt;65 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Albumin: Product is stabilized with albumin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents (eg, viruses, the variant Creutzfeldt Jakob disease agent, theoretically the Creutzfeldt Jakob disease agent) that could transmit disease, including unknown or emerging viruses and other pathogens. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduce the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sucrose: Product is stabilized with sucrose.</p></div>
<div class="block foc drugH1Div" id="F156142"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injectable, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cytogam: 50 mg/mL (50 mL) [contains albumin human]</p></div>
<div class="block geq drugH1Div" id="F156128"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323090"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Injection</b> (Cytogam Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $42.16</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55361442"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injectable, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cytogam: 50 mg/mL (50 mL) [contains albumin human]</p></div>
<div class="block adip drugH1Div" id="F53565902"><span class="drugH1">Additional Information</span>
<p style="text-indent:-2em;margin-left:2em;">IgA content: Trace</p>
<p style="text-indent:-2em;margin-left:2em;">Albumin: 10 mg/mL</p>
<p style="text-indent:-2em;margin-left:2em;">Sodium content: 20 to 30 mEq/L</p>
<p style="text-indent:-2em;margin-left:2em;">Sugar content: 5% sucrose</p>
<p style="text-indent:-2em;margin-left:2em;">Osmolality: &gt;200 mOsm/L</p></div>
<div class="block admp drugH1Div" id="F52612475"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;">Parenteral: IV infusion: Does not require further dilution; administer as a 50 mg/mL solution through a dedicated IV line containing an in-line 15 micron filter (a 0.2 micron filter is also acceptable) using an infusion pump. Do not mix with other infusions; do not use if turbid; do not shake solution. Begin infusion within 6 hours of entering vial, complete infusion within 12 hours of vial entry. Infusion with other products is not recommended; however, if unavoidable, may be piggybacked into an IV line of NS, D5W, D10W, or dextrose 20% in water; however, do not dilute more than 1:2.</p>
<p style="text-indent:0em;margin-top:2em;">Initial infusion: Begin at 15 mg/kg/hour; if there are no infusion-related reactions after 30 minutes, increase to 30 mg/kg/hour; if no infusion-related reactions after 30 minutes, may increase to 60 mg/kg/hour for the remainder of the infusion; infusion rate should not exceed 75 mL/hour. Monitor closely during and after each rate change. If patient develops nausea, back pain, or flushing during infusion, slow the rate or temporarily stop the infusion. Discontinue if blood pressure drops or in case of anaphylactic reaction.</p>
<p style="text-indent:0em;margin-top:2em;">Subsequent infusions: Initiate at 15 mg/kg/hour for the first 15 minutes, if no infusion-related reactions, increase to 30 mg/kg/hour for the next 15 minutes; if rate is tolerated, increase to 60 mg/kg/hour and maintain this rate until completion of dose; maximum infusion rate: 60 mg/kg/hour or not to exceed 75 mL/hour.</p></div>
<div class="block adm drugH1Div" id="F156145"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer through an IV line containing an in-line 15 micron filter (a 0.2 micron filter is also acceptable) using an infusion pump. The solution must be free of particulate matter and colorless. Do not mix with other infusions; do not use if turbid. Begin infusion within 6 hours of entering vial, complete infusion within 12 hours of vial entry.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Initial dose:</i> Infuse at 15 mg/kg/hour. If no adverse reactions occur within 30 minutes, may increase rate to 30 mg/kg/hour. If no adverse reactions occur within the second 30 minutes, may increase rate to 60 mg/kg/hour; maximum rate of infusion: 75 mL/hour. Monitor closely after each rate change. If patient develops nausea, back pain, or flushing during infusion, slow the rate or temporarily stop the infusion. Discontinue if blood pressure drops or in case of anaphylactic reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Subsequent doses:</i> Infuse at 15 mg/kg/hour for 15 minutes; if no adverse reactions occur, may increase rate to 30 mg/kg/hour for 15 minutes; if no adverse reactions occur, may increase rate to 60 mg/kg/hour; maximum rate of infusion: 75 mL/hour.</p></div>
<div class="block sts drugH1Div" id="F156151"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store refrigerated between 2°C and 8°C (36°F and 46°F). Infusion should begin within 6 hours after entering the vial.</p></div>
<div class="block usep drugH1Div" id="F53566333"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prophylaxis of cytomegalovirus (CMV) disease associated with kidney, lung, liver, pancreas, or heart transplantation (FDA approved in pediatric patients [age not specified] and adults); has also been used for prophylaxis of CMV disease associated with intestinal (eg, small bowel) transplantation; treatment of CMV infection for severe pneumonitis (in combination with ganciclovir) or if ganciclovir resistant; and for treatment of infantile hemolytic anemia due to CMV</p></div>
<div class="block mst drugH1Div" id="F156182"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">CytoGam may be confused with Cytoxan, Gamimune N</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299116"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F156136"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for as long as 6 to 11 months following immune globulin administration. Recommendations vary by product and immune globulin dose, see full monograph for details.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F4813545"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May contain sodium.</p></div>
<div class="block pri drugH1Div" id="F156149"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cytomegalovirus (CMV) immune globulin is obtained from pooled human plasma and primarily contains IgG. Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">CMV immune globulin has been evaluated for the treatment and prevention of congenital CMV infection (Devlieger 2021; Hughes 2021; Revello 2014). Maternal CMV infection may be associated with adverse pregnancy outcomes including congenital CMV infection; however, until additional data are available, use of CMV immune globulin for the treatment of congenital CMV infection outside of a clinical trial is not currently recommended (SMFM 2016).</p></div>
<div class="block mopp drugH1Div" id="F53566332"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function (BUN, serum creatinine prior to initial infusion and periodically thereafter); urine output; vital signs, including blood pressure (throughout infusion); signs/symptoms of infusion-related adverse reactions, anaphylaxis; signs and symptoms of hemolytic anemia; blood viscosity (baseline; in patients at risk for hyperviscosity); presence of antineutrophil antibodies (if TRALI is suspected); volume status; weight gain; clinical response (presence or resolution of signs and symptoms of CMV infection; CMV-PCR levels)</p></div>
<div class="block pha drugH1Div" id="F156131"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">CMV-IGIV is a preparation of immunoglobulin G (and trace amounts of IgA and IgM) derived from pooled healthy blood donors and contains a high titer of CMV antibodies; administration provides a passive source of antibodies against cytomegalovirus to attenuate or reduce the incidence of serious CMV disease </p></div>
<div class="block phk drugH1Div" id="F45755632"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Half-life elimination: 8 to 24 days</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F3462463"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Megalotect</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cytoglobin | Cytotect | Cytotect cp biotest</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ivegam-cmv | Megalotect</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cytotect cp biotest</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Megalotect | Megalotect cp</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cytotect</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cytoglobin | Cytotect</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cytotect cp</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Megalotect</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Megalotect</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cytotect cp biotest</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cytotect cp | Megalotect</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Megalotect</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cytomegatect | Cytotect</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Megalotect</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Megalotect</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Megalotect</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cytogam | Cytotect</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cytogam</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Megalotect</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cytotect | Neocytotect</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cytotect</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Megalotect</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cytotect</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Megalotect</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cytogam</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cytotect</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Megalotect</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-20500045">
<a name="20500045"></a>Alexander BT, Hladnik LM, Augustin KM, et al, “Use of Cytomegalovirus Intravenous Immune Globulin for the Adjunctive Treatment of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients,” <i>Pharmacotherapy</i>, 2010, 30(6):554-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/20500045/pubmed" id="20500045" target="_blank">20500045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1651360">
<a name="1651360"></a>Bowden RA, Fisher LD, Rogers K, et al, “Cytomegalovirus (CMV)-Specific Intravenous Immunoglobulin for the Prevention of Primary CMV Infection and Disease After Marrow Transplant,” <i>J Infect Dis</i>, 1991, 164(3):483-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/1651360/pubmed" id="1651360" target="_blank">1651360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11994033">
<a name="11994033"></a>Bueno J, Ramil C, and Green M, "Current Management Strategies for the Prevention and Treatment of Cytomegalovirus Infection in Pediatric Transplant Recipients," <i>Paediatr Drugs</i>, 2002, 4(5):279-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/11994033/pubmed" id="11994033" target="_blank">11994033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10401909">
<a name="10401909"></a>Centers for Disease Control and Prevention (CDC). Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998. <i>MMWR Morb Mortal Wkly Rep</i>. 1999;48(24):518-521.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/10401909/pubmed" id="10401909" target="_blank">10401909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cytogam (cytomegalovirus immune globulin intravenous [human]) [prescribing information]. Hoboken, NJ: Kamada Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34569538">
<a name="34569538"></a>Devlieger R, Buxmann H, Nigro G, et al. Serial monitoring and hyperimmunoglobulin versus standard of care to prevent congenital cytomegalovirus infection: a phase III randomized trial.<i> Fetal Diagn Ther.</i> 2021;48(8):611-623. doi:10.1159/000518508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/34569538/pubmed" id="34569538" target="_blank">34569538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34320288">
<a name="34320288"></a>Hughes BL, Clifton RG, Rouse DJ, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. A trial of hyperimmune globulin to prevent congenital cytomegalovirus infection.<i> N Engl J Med.</i> 2021;385(5):436-444. doi:10.1056/NEJMoa1913569<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/34320288/pubmed" id="34320288" target="_blank">34320288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20070700">
<a name="20070700"></a>Humar A, and Snydman D, “Cytomegalovirus in solid organ transplant recipients,” <i>Am J Transplant</i>, 2009, 9(Suppl 4):578-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/20070700/pubmed" id="20070700" target="_blank">20070700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23896556">
<a name="23896556"></a>Kotton CN, Kumar D, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid organ transplantation. <i>Transplantation</i>. 2013;96(4):333-360.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/23896556/pubmed" id="23896556" target="_blank">23896556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21199215">
<a name="21199215"></a>Martin JM, Danziger-Isakov LA. Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation. <i>Pediatr Transplant</i>. 2011;15(3):229-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/21199215/pubmed" id="21199215" target="_blank">21199215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11464992">
<a name="11464992"></a>Murray JC, Bernini JC, Bijou HL, Rossmann SN, Mahoney DH Jr, Morad AB. Infantile cytomegalovirus-associated autoimmune hemolytic anemia. <i>J Pediatr Hematol Oncol</i>. 2001;23(5):318-320.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/11464992/pubmed" id="11464992" target="_blank">11464992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26247555">
<a name="26247555"></a>Nagai S, Mangus RS, Anderson E, et al. Cytomegalovirus infection after intestinal/multivisceral transplantation: a single-center experience with 210 cases. <i>Transplantation</i>. 2016;100(2):451-460.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/26247555/pubmed" id="26247555" target="_blank">26247555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol.</i> 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23465003">
<a name="23465003"></a>Razonable RR, Humar A and the AST Infectious Disease Community of Practice. Cytomegalovirus in solid organ transplantation. <i>Am J Transplant</i>. 2013;13(Suppl 4):93-106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/23465003/pubmed" id="23465003" target="_blank">23465003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3040870">
<a name="3040870"></a>Reed EC, Bowden RA, Dandliker PS, et al, “Efficacy of Cytomegalovirus Immunoglobulin in Marrow Transplant Recipients With Cytomegalovirus Pneumonia,” <i>J Infect Dis</i>, 1987, 156(4):641-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/3040870/pubmed" id="3040870" target="_blank">3040870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2847610">
<a name="2847610"></a>Reed EC, Bowden RA, Dandliker PS, et al, “Treatment of Cytomegalovirus Pneumonia With Ganciclovir and Intravenous Cytomegalovirus Immunoglobulin in Patients With Bone Marrow Transplants,” <i>Ann Intern Med</i>, 1988, 109(10):783-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/2847610/pubmed" id="2847610" target="_blank">2847610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24693891">
<a name="24693891"></a>Revello MG, Lazzarotto T, Guerra B, et al; CHIP Study Group. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus.<i> N Engl J Med.</i> 2014;370(14):1316-1326. doi:10.1056/NEJMoa1310214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/24693891/pubmed" id="24693891" target="_blank">24693891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8214995">
<a name="8214995"></a>Snydman DR, Werner BG, Dougherty NN, et al, “Cytomegalovirus Immune Globulin Prophylaxis in Liver Transplantation. A Randomized, Double-Blind, Placebo-Controlled Trial,” <i>Ann Intern Med</i>, 1993, 119(10):984-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/8214995/pubmed" id="8214995" target="_blank">8214995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26902990">
<a name="26902990"></a>Society for Maternal-Fetal Medicine (SMFM); Hughes BL, Gyamfi-Bannerman C. Diagnosis and antenatal management of congenital cytomegalovirus infection. <i>Am J Obstet Gynecol.</i> 2016;214(6):B5-B11. doi:10.1016/j.ajog.2016.02.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/26902990/pubmed" id="26902990" target="_blank">26902990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11939601">
<a name="11939601"></a>Sokos DR, Berger M, and Lazarus HM, “Intravenous Immunoglobulin: Appropriate Indications and Uses in Hematopoietic Stem Cell Transplantation,” <i>Biol Blood Marrow Transplant</i>, 2002, 8(3):117-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/11939601/pubmed" id="11939601" target="_blank">11939601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11726825">
<a name="11726825"></a>Valantine HA, Luikart H, Doyle R, et al, “Impact of Cytomegalovirus Hyperimmune Globulin on Outcome After Cardiothoracic Transplantation: A Comparative Study of Combined Prophylaxis With CMV Hyperimmune Globulin Plus Ganciclovir Versus Ganciclovir Alone,” <i>Transplantation</i>, 2001, 72(10):1647-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/11726825/pubmed" id="11726825" target="_blank">11726825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15367218">
<a name="15367218"></a>Zamora MR, Nicolls MR, Hodges TN, et al, “Following Universal Prophylaxis With Intravenous Ganciclovir and Cytomegalovirus Immune Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection Following Lung Transplantation,” <i>Am J Transplant,</i> 2004, 4(10):1635-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/15367218/pubmed" id="15367218" target="_blank">15367218</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12926 Version 159.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
